{"title":"与贸易有关的知识产权协定对获得免疫抑制药物的影响:发展中国家肾移植和治疗的另一个挑战","authors":"Oyeniyi Ajigboye, Ifeoluwa A. Olubiyi","doi":"10.3366/AJICL.2021.0365","DOIUrl":null,"url":null,"abstract":"Kidney transplantation (KT) as a medical treatment for end-stage renal disease (ESRD) is cost-effective even in developing countries and this treatment has continued to record good success rates. Despite this positive development, the practice of KT continues to face varying challenges across developed and developing countries alike. In developing countries, however, the management of post-transplantation issues is a major challenge. The discovery of immunosuppressant drugs, the accessibility of these drugs and technological advancements that reduce the impact of pre- and post-transplant issues in developed countries is still not readily available in developing countries. This is largely because of restricted access to immunosuppressants and the availability of medications for post-transplant conditions. This article therefore highlights and discusses the implications of the Agreement on the Trade Related Aspects of Intellectual Property Rights (TRIPS Agreement) on the access to immunosuppressant drugs in developing countries. The authors conclude that although the TRIPS Agreement continues to hinder the desired access to immunosuppressants thereby worsening the prospects of KT recipients in developing countries, these countries should maximise the flexibilities available under the treaty to improve access to immunosuppressant drugs.","PeriodicalId":42692,"journal":{"name":"African Journal of International and Comparative Law","volume":"29 1","pages":"309-324"},"PeriodicalIF":0.3000,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of TRIPs Agreement on Access to Immunosuppressant Drugs: Another Challenge in Kidney Transplantation and Treatment in Developing Countries\",\"authors\":\"Oyeniyi Ajigboye, Ifeoluwa A. Olubiyi\",\"doi\":\"10.3366/AJICL.2021.0365\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Kidney transplantation (KT) as a medical treatment for end-stage renal disease (ESRD) is cost-effective even in developing countries and this treatment has continued to record good success rates. Despite this positive development, the practice of KT continues to face varying challenges across developed and developing countries alike. In developing countries, however, the management of post-transplantation issues is a major challenge. The discovery of immunosuppressant drugs, the accessibility of these drugs and technological advancements that reduce the impact of pre- and post-transplant issues in developed countries is still not readily available in developing countries. This is largely because of restricted access to immunosuppressants and the availability of medications for post-transplant conditions. This article therefore highlights and discusses the implications of the Agreement on the Trade Related Aspects of Intellectual Property Rights (TRIPS Agreement) on the access to immunosuppressant drugs in developing countries. The authors conclude that although the TRIPS Agreement continues to hinder the desired access to immunosuppressants thereby worsening the prospects of KT recipients in developing countries, these countries should maximise the flexibilities available under the treaty to improve access to immunosuppressant drugs.\",\"PeriodicalId\":42692,\"journal\":{\"name\":\"African Journal of International and Comparative Law\",\"volume\":\"29 1\",\"pages\":\"309-324\"},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2021-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"African Journal of International and Comparative Law\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3366/AJICL.2021.0365\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"LAW\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"African Journal of International and Comparative Law","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3366/AJICL.2021.0365","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"LAW","Score":null,"Total":0}
Impact of TRIPs Agreement on Access to Immunosuppressant Drugs: Another Challenge in Kidney Transplantation and Treatment in Developing Countries
Kidney transplantation (KT) as a medical treatment for end-stage renal disease (ESRD) is cost-effective even in developing countries and this treatment has continued to record good success rates. Despite this positive development, the practice of KT continues to face varying challenges across developed and developing countries alike. In developing countries, however, the management of post-transplantation issues is a major challenge. The discovery of immunosuppressant drugs, the accessibility of these drugs and technological advancements that reduce the impact of pre- and post-transplant issues in developed countries is still not readily available in developing countries. This is largely because of restricted access to immunosuppressants and the availability of medications for post-transplant conditions. This article therefore highlights and discusses the implications of the Agreement on the Trade Related Aspects of Intellectual Property Rights (TRIPS Agreement) on the access to immunosuppressant drugs in developing countries. The authors conclude that although the TRIPS Agreement continues to hinder the desired access to immunosuppressants thereby worsening the prospects of KT recipients in developing countries, these countries should maximise the flexibilities available under the treaty to improve access to immunosuppressant drugs.